Merck stock tumbled amid a broad pharma turndown Thursday even though the company racked up more than $5 billion in sales for its blockbuster cancer drug, Keytruda.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,